Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: Biologic significance and potential role in therapeutic stratification of patients

American Journal of Surgical Pathology

Volumn 31, Issue 11, 2007, Pages 1645-1652

  Williams, Michelle D ^a   Roberts, Dianna ^a   Blumenschein Jr , George R ^a   Temam, Stephane ^a   Kies, Merrill S ^a   Rosenthal, David I ^a   Weber, Randal S ^a   El Naggar, Adel K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Androgen receptor; Epidermal growth factor; Estrogen receptor ; HER 2; Salivary duct carcinoma

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR BETA; GLUTAMIC ACID; GROWTH FACTOR RECEPTOR; HORMONE RECEPTOR; LEUCINE RICH PROTEIN 1; PROLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; DOWN-REGULATION; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PHENOTYPE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349018981     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3180caa099     Document Type: Article

References (59)

1. AMA Committee on Research. Androgens and estrogens in the treatment of disseminated mammary carcinoma. J Am Med Assoc. 1960;172:1271-1274.
2. Bardin A, Boulle N, Lazennec G, et al. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537-551.
3. Barnes DM. c-erbB-2 amplification in mammary carcinoma. J Cell Biochem Suppl. 1993;17G:132-138.
4. Barnes L, Rao U, Contis L, et al. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78:74-80.
5. Barnes L, Rao U, Krause J, et al. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78:64-73.
6. Buchanan G, Birrell SN, Peters AA, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005;65:8487-8496.
7. Dagrada GP, Negri T, Tamborini E, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2004;44:301-302.
8. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72:1503-1512.
9. Dimery IW, Jones LA, Verjan RP, et al. Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 1987;113:1082-1085.
10. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10:292-298.
11. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24:579-586.
12. Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor á in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1075-1079.
13. Foley EF, Jazaeri AA, Shupnik MA, et al. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 2000;60:245-248.
14. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003;63:2434-2439.
15. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944-946.
16. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. Chicago, IL: American Joint Committee on Cancer; 2002.
17. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724-727.
18. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988;48:246-253.
19. Hoang MP, Callender DL, Sola Gallego JJ, et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol. 2001;19:865-871.
20. Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103:2526-2533.
21. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038.
22. Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003;63:1-5.
23. Katopodi E, Patsouris E, Papanikolaou V, et al. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:266-268.
24. Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192:100-105.
25. Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992;13:3-17.
26. Kuiper GG, Gustafsson JA. The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997;410:87-90.
27. Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. 1999;59:1175-1179.
28. Liu Y, Majumder S, McCall W, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005;65:3404-3409.
29. Maggiolini M, Recchia AG, Carpino A, et al. Oestrogen receptor β is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol. 2004;32:777-791.
30. Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996;74:1253-1257.
31. Mellinghoff IK, Vivanco I, Kwon A, et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517-527.
32. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006;12:4790-4793.
33. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors: frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801-806.
34. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl 4):S9-S15.
35. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. 2000;59:753-767.
36. Ortmann J, Prifti S, Bohlmann MK, et al. Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16:113-120.
37. Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor β in breast cancer. Endocr Relat Cancer. 2002;9:1-13.
38. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene. 2000;19:4970-4978.
39. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17-35.
40. Rajhans R, Vadlamudi RK. Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis. 2006. [ahead of print].
41. Rayala SK, Hollander P, Balasenthil S, et al. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem. 2006;281:4395-4403.
42. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1 suppl 1):S53-S67.
43. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002;94:384-390.
44. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926-935.
45. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene. 2004;23:7979-7989.
46. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42:348-356.
47. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201:213-220.
48. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;235:177-182.
49. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
50. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. 2004;5:174-181.
51. Strom A, Hartman J, Foster JS, et al. Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004;101:1566-1571.
52. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg. 2004;139:50-54.
53. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets. 2003;7:215-234.
54. Vadlamudi RK, Balasenthil S, Broaddus RR, et al. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab. 2004;89:6130-6138.
55. Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ERβ expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol. 2005;36:670-675.
56. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res. 2005;65:7724-7732.
57. Watson PA, Kim K, Chen KS, et al. Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto-oncogene. Cancer Cell. 2002;2:67-79.
58. Wick MR, Ockner DM, Mills SE, et al. Homologous carcinomas of the breasts, skin, and salivary glands: a histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998;109:75-84.
59. Wong NA, Malcomson RD, Jodrell DI, et al. ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol. 2005;207:53-60.